Clinical bottom line
Novel anti-IL-23 therapies represent a promising, yet still investigational, approach for patients with treatment-resistant lupus nephritis (LN). Early-phase clinical data and mechanistic studies suggest that targeting the IL-23/IL-17 axis may modulate pathogenic immune responses implicated in LN. However, robust randomized controlled trial evidence remains limited, and these agents are not yet established in routine clinical practice. Clinicians should consider anti-IL-23 therapies as a potential future option pending further validation, especially for patients with refractory disease who have exhausted conventional immunosuppressive regimens.
What the evidence shows
Lupus nephritis is a severe manifestation of systemic lupus erythematosus characterized by immune complex deposition and inflammatory injury in the kidneys. Despite advances in immunosuppressive therapy, a subset of patients remains refractory or intolerant to current treatments (Lee et al., 2026). The IL-23/IL-17 pathway has emerged as a key driver of autoimmune inflammation, promoting Th17 cell differentiation and proinflammatory cytokine production implicated in LN pathogenesis (Santacruz et al., 2021).
Preclinical and translational studies have demonstrated elevated IL-23 and IL-17 levels in LN patients, correlating with disease activity and renal damage. This has spurred interest in IL-23 blockade as a novel therapeutic strategy. Santacruz et al. (2021) reviewed current evidence supporting IL-17/23 inhibitors, highlighting their immunomodulatory potential and rationale for LN treatment. Although approved IL-23 inhibitors are established in psoriasis and other autoimmune diseases, their application in LN is still emerging.
Clinical data remain preliminary. Furie et al. (2022) summarized new and approved therapies for LN, noting ongoing trials evaluating IL-23 inhibitors in refractory cases. Tahir et al. (2005) provided an earlier overview of novel therapies, underscoring the unmet need for targeted agents in resistant LN. Current evidence suggests that IL-23 blockade may reduce renal inflammation and proteinuria, but definitive efficacy and safety data from large randomized controlled trials are lacking.
Caveats and uncertainty
The evidence supporting anti-IL-23 therapies in LN is largely hypothesis-generating and derived from small studies, preclinical models, or extrapolation from other autoimmune diseases. The heterogeneity of LN phenotypes and immunopathology complicates patient selection and response prediction. Additionally, the long-term safety profile of IL-23 inhibitors in LN patients, who often require prolonged immunosuppression, remains unknown.
Existing immunosuppressive regimens, including corticosteroids, mycophenolate mofetil, cyclophosphamide, and biologics such as rituximab and belimumab, have established efficacy and safety profiles. Anti-IL-23 agents have yet to demonstrate superiority or additive benefit over these standards. Furthermore, the potential for increased infection risk or other adverse effects with IL-23 blockade warrants careful evaluation.
Given these uncertainties, anti-IL-23 therapies should currently be considered experimental in LN. Their use outside clinical trials is not recommended until more robust evidence is available.
How this may change practice
If ongoing and future clinical trials confirm the efficacy and safety of anti-IL-23 therapies in treatment-resistant LN, these agents could expand the therapeutic armamentarium for this challenging population. They may offer a targeted alternative for patients who fail or cannot tolerate conventional immunosuppression, potentially improving renal outcomes and reducing treatment-related toxicity.
Clinicians should remain informed about emerging data on IL-23 blockade and consider referral of eligible patients to clinical trials. Integration of IL-23 inhibitors into LN management will require careful patient selection, monitoring, and coordination with multidisciplinary teams. Until then, established immunosuppressive protocols remain the cornerstone of LN treatment.